BACKGROUND: Patients with pulmonary hypertension (PH) due to chronic lung disease (Group 3 PH) have poor long-term outcomes. However, predictors of survival in Group 3 PH are not well described.
METHODS: We performed a cohort study of Group 3 PH patients (n = 143; mean age 65 ± 12 years, 52% female) evaluated at the University of Minnesota. The Kaplan-Meier method and Cox regression analysis were used to assess survival and predictors of mortality, respectively. The clinical characteristics and survival were compared in patients categorized by PH severity based on the World Health Organization (WHO) classification and lung disease etiology.
RESULTS: After a median follow-up of 1.4 years, there were 69 (48%) deaths. The 1-, 3-, and 5-year survival rates were 79%, 48%, and 31%. Age, coronary artery disease, atrial fibrillation, Charlson comorbidity index, serum N-terminal pro‒brain natriuretic peptide (NT-proBNP), creatinine, diffusion capacity of carbon monoxide (DLCO), total lung capacity, left ventricular ejection fraction, right atrial and right ventricular enlargement on echocardiography, cardiac index, and pulmonary vascular resistance (PVR) were univariate predictors of survival. On multivariable analysis, DLCO was the only predictor of mortality (adjusted hazard ratio [HR] for every 10% decrease in predicted value: 1.31 [95% confidence interval 1.12 to 1.47]; p = 0.003). The 1-/5-year survival by tertiles of DLCO was 84%/56%, 82%/44%, and 63%/14% (p = 0.01), respectively. On receiver-operating characteristic curve analysis, DLCO <32% of predicted had the highest sensitivity and specificity for predicting survival. The 1- and 5-year survival in patients with a DLCO ≥32% predicted was 84% and 60% vs 68% and 13% in patients with a DLCO <32% predicted (adjusted HR: 2.5 [95% confidence interval 1.3 to 5.0]; p = 0.007). Lung volumes and DLCO were not related, but higher PVR was strongly associated with reduced DLCO. There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival.
CONCLUSIONS: Low DLCO is a predictor of mortality and should be used to risk-stratify Group 3 PH patients.
|Original language||English (US)|
|Number of pages||11|
|Journal||Journal of Heart and Lung Transplantation|
|State||Published - Feb 2019|
Bibliographical noteFunding Information:
The authors have no conflicts of interest to disclose. TT received modest honorarium from Gilead sciences and Actelion for serving on the advisory board. This study was supported by grants from the National Institutes of Health (NIH F32 HL129554 and NIH K08 HL140100 to K.W.P., and NIH RO1 HL113003 to SLA); the Canada Foundation for Innovation ( 229252 and 33012 to SLA); a Tier 1 Canada Research Chair in Mitochondrial Dynamics and Translational Medicine ( 950-229252 to SLA); the William J Henderson Foundation to SLA; and the American Heart Association (Scientist Development Grant 15SDG25560048 to T.T.).
The authors have no conflicts of interest to disclose. TT received modest honorarium from Gilead sciences and Actelion for serving on the advisory board. This study was supported by grants from the National Institutes of Health (NIH F32 HL129554 and NIH K08 HL140100to K.W.P., and NIH RO1 HL113003to SLA); the Canada Foundation for Innovation (229252 and 33012to SLA); a Tier 1 Canada Research Chair in Mitochondrial Dynamics and Translational Medicine (950-229252to SLA); the William J Henderson Foundation to SLA; and the American Heart Association (Scientist Development Grant 15SDG25560048to T.T.).
© 2018 Elsevier Ltd
- Cor pulmonale
- Interstitial lung disease
- pulmonary function test
- right ventricle